Novo Nordisk, Eli Lilly stocks see boost on obesity drugs

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 10 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 7%
  • Publisher: 63%

Business News News

Business Business Latest News,Business Business Headlines

Novo Nordisk (NVO) shares rose as the drugmaker's third-quarter profits jumped 56% year-over-year, fueled by surging demand for its obesity drugs Ozempic and...

The Canadian company reported adjusted earnings per share of four cents in Q2, versus a loss of five cents in Q2 2022) shares also saw gains after beating third-quarter profit

estimates, but lowering its full-year guidance. The drugmaker is gaining momentum from its diabetes drug Mounjaro, though it still lacks regulatory approval for obesity treatment.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 47. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines